FDA

There seems to be an inclination among policy-makers that adherence to evidence-based policy-making is a luxury we can only afford when not in a crisis.

If the COVID-19 crisis has taught us one thing—aside from the need to wash your hands often—it is that the FDA’s approval process for much-needed medicine to those with debilitating and terminal diseases is in dire need of reform.

Now that the Trump Administration’s new FDA commissioner, Dr. Stephen Hahn, has been confirmed, he’ll find he has one of the most difficult and important jobs in government.

Nearly six million Americans of all ages are living with Alzheimer’s disease, and more than 16 million Americans care for people living with Alzheimer’s and other dementias.

The fake news media and ignorant politicians have shamefully perpetuated a myth that “vaping” is responsible for more than 500 hospitalizations and seven deaths.

When products could save lives, it’s important for people to be informed about those benefits, along with the risks.

FDA must no longer let organic food growers, manufacturers and sellers get away with lies.

Americans suffering from debilitating diseases should not have to lobby Congress or Food and Drug Administration (FDA) bureaucrats for special permission to access potentially lifesaving treatments.

For Jaci Hermstad and many others suffering from debilitating diseases such as amyotrophic lateral sclerosis (ALS), time and treatment options are limited.

Should teenagers vape, text while driving, use marijuana, drink alcohol?  Absolutely not.  Demonizing vapor products only destroys public perception, scares adult smokers from converting, and financially harms small businesses.

Words matter. For example, when the head of the U.S. Food and Drug Administration (FDA) decries an “epidemic,” the media and state policymakers pay attention.

When products have the potential to save millions of lives, it’s helpful if people are told about those benefits.

Today marks the 30th World AIDS Day.